2SEVENTY BIO INC (TSVT) Stock Price, Forecast & Analysis
NASDAQ:TSVT • US9013841070
TSVT Key Statistics, Chart & Performance
The current stock price of TSVT is 5 USD. In the past month the price increased by 0.81%. In the past year, price increased by 4.17%.
TSVT Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to TSVT. When comparing the yearly performance of all stocks, TSVT is one of the better performing stocks in the market, outperforming 95.69% of all stocks.
TSVT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TSVT. The financial health of TSVT is average, but there are quite some concerns on its profitability.
TSVT Financial Highlights
Over the last trailing twelve months TSVT reported a non-GAAP Earnings per Share(EPS) of -1.12. The EPS increased by 72.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.94% | ||
| ROE | -27.16% | ||
| Debt/Equity | 0 |
TSVT Forecast & Estimates
8 analysts have analysed TSVT and the average price target is 5.1 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 5.
For the next year, analysts expect an EPS growth of 58.41% and a revenue growth 42.31% for TSVT
TSVT Ownership
TSVT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.13 | 414.026B | ||
| AMGN | AMGEN INC | 17.12 | 207.692B | ||
| GILD | GILEAD SCIENCES INC | 16.82 | 186.139B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.84 | 123.316B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.02 | 83.604B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.53 | 42.945B | ||
| INSM | INSMED INC | N/A | 31.206B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 12.36 | 27.598B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.2 | 22.521B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TSVT
Company Profile
2seventy Bio, Inc. operates as cell and gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 65 full-time employees. The company went IPO on 2021-10-18. The firm is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS). ABECMA is a BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma uses a lentiviral vector (LVV), to deliver a chimeric antigen receptor (CAR), with the potential to program a patient’s own T cells to recognize the plasma cell specific BCMA, protein on the cell surface.
Company Info
2SEVENTY BIO INC
60 Binney Street
Cambridge MASSACHUSETTS US
Employees: 274
Phone: 13394999300
2SEVENTY BIO INC / TSVT FAQ
What does 2SEVENTY BIO INC do?
2seventy Bio, Inc. operates as cell and gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 65 full-time employees. The company went IPO on 2021-10-18. The firm is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS). ABECMA is a BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma uses a lentiviral vector (LVV), to deliver a chimeric antigen receptor (CAR), with the potential to program a patient’s own T cells to recognize the plasma cell specific BCMA, protein on the cell surface.
What is the current price of TSVT stock?
The current stock price of TSVT is 5 USD. The price increased by 0.2% in the last trading session.
Does 2SEVENTY BIO INC pay dividends?
TSVT does not pay a dividend.
What is the ChartMill technical and fundamental rating of TSVT stock?
TSVT has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does 2SEVENTY BIO INC belong to?
2SEVENTY BIO INC (TSVT) operates in the Health Care sector and the Biotechnology industry.
What is the employee count for TSVT stock?
2SEVENTY BIO INC (TSVT) currently has 274 employees.
Can you provide the ownership details for TSVT stock?
You can find the ownership structure of 2SEVENTY BIO INC (TSVT) on the Ownership tab.